132 related articles for article (PubMed ID: 35431121)
21. SpaceOAR Hydrogel Spacer for Reducing Radiation Toxicity During Radiotherapy for Prostate Cancer. A Systematic Review.
Armstrong N; Bahl A; Pinkawa M; Ryder S; Ahmadu C; Ross J; Bhattacharyya S; Woodward E; Battaglia S; Binns J; Payne H
Urology; 2021 Oct; 156():e74-e85. PubMed ID: 34029607
[TBL] [Abstract][Full Text] [Related]
22. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.
Michalski JM; Purdy JA; Winter K; Roach M; Vijayakumar S; Sandler HM; Markoe AM; Ritter MA; Russell KJ; Sailer S; Harms WB; Perez CA; Wilder RB; Hanks GE; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):391-402. PubMed ID: 10661346
[TBL] [Abstract][Full Text] [Related]
23. No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity.
Barnett GC; Kerns SL; Dorling L; Fachal L; Aguado-Barrera ME; Martínez-Calvo L; Jandu HK; Welsh C; Tyrer J; Coles CE; Haviland JS; Parker C; Gómez-Caamaño A; Calvo-Crespo P; Sosa-Fajardo P; Burnet NG; Summersgill H; Webb A; De Ruysscher D; Seibold P; Chang-Claude J; Talbot CJ; Rattay T; Parliament M; De Ruyck K; Rosenstein BS; Pharoah PDP; Dunning AM; Vega A; West CML;
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):494-501. PubMed ID: 35840111
[TBL] [Abstract][Full Text] [Related]
24. Acute and Late Adverse Events Associated With Radical Radiation Therapy Prostate Cancer Treatment: A Systematic Review of Clinician and Patient Toxicity Reporting in Randomized Controlled Trials.
Holch P; Henry AM; Davidson S; Gilbert A; Routledge J; Shearsmith L; Franks K; Ingleson E; Albutt A; Velikova G
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):495-510. PubMed ID: 28126299
[TBL] [Abstract][Full Text] [Related]
25. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
[TBL] [Abstract][Full Text] [Related]
26. The effect of race/ethnicity on prostate cancer treatment outcome is conditional: a review of Wayne State University data.
Powell IJ; Banerjee M; Bianco FJ; Wood DP; Dey J; Lai Z; Heath M; Pontes EJ
J Urol; 2004 Apr; 171(4):1508-12. PubMed ID: 15017209
[TBL] [Abstract][Full Text] [Related]
27. Predicting toxicity in radiotherapy for prostate cancer.
Landoni V; Fiorino C; Cozzarini C; Sanguineti G; Valdagni R; Rancati T
Phys Med; 2016 Mar; 32(3):521-32. PubMed ID: 27068274
[TBL] [Abstract][Full Text] [Related]
28. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer.
Seibold P; Webb A; Aguado-Barrera ME; Azria D; Bourgier C; Brengues M; Briers E; Bultijnck R; Calvo-Crespo P; Carballo A; Choudhury A; Cicchetti A; Claßen J; Delmastro E; Dunning AM; Elliott RM; Fachal L; Farcy-Jacquet MP; Gabriele P; Garibaldi E; Gómez-Caamaño A; Gutiérrez-Enríquez S; Higginson DS; Johnson K; Lobato-Busto R; Mollà M; Müller A; Payne D; Peleteiro P; Post G; Rancati T; Rattay T; Reyes V; Rosenstein BS; De Ruysscher D; De Santis MC; Schäfer J; Schnabel T; Sperk E; Symonds RP; Stobart H; Taboada-Valladares B; Talbot CJ; Valdagni R; Vega A; Veldeman L; Ward T; Weißenberger C; West CML; Chang-Claude J;
Radiother Oncol; 2019 Sep; 138():59-67. PubMed ID: 31146072
[TBL] [Abstract][Full Text] [Related]
29. High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up.
Hou Z; Li G; Bai S
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1063-71. PubMed ID: 25173623
[TBL] [Abstract][Full Text] [Related]
30. Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control.
Jani AB; Blend MJ; Hamilton R; Brendler C; Pelizzari C; Krauz L; Sapra B; Vijayakumar S; Awan A; Weichselbaum RR
J Nucl Med; 2004 Aug; 45(8):1315-22. PubMed ID: 15299055
[TBL] [Abstract][Full Text] [Related]
31. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.
Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M
Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713
[TBL] [Abstract][Full Text] [Related]
32. Variations in Age-Adjusted Prostate Cancer Incidence Rates by Race and Ethnicity After Changes in Prostate-Specific Antigen Screening Recommendation.
Lai SM; Keighley J; Garimella S; Enko M; Parker WP
JAMA Netw Open; 2022 Nov; 5(11):e2240657. PubMed ID: 36342715
[TBL] [Abstract][Full Text] [Related]
33. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
34. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
35. Reporting late rectal toxicity in prostate cancer patients treated with curative radiation treatment.
Faria SL; Souhami L; Joshua B; Vuong T; Freeman CR
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):777-81. PubMed ID: 18411000
[TBL] [Abstract][Full Text] [Related]
36. Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis.
David R; Buckby A; Kahokehr AA; Lee J; Watson DI; Leung J; O'Callaghan ME
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):8-15. PubMed ID: 35260794
[TBL] [Abstract][Full Text] [Related]
37. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
38. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
[TBL] [Abstract][Full Text] [Related]
39. Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy.
Thurner EM; Krenn-Pilko S; Langsenlehner U; Renner W; Gerger A; Kapp KS; Langsenlehner T
Strahlenther Onkol; 2014 Mar; 190(3):304-9. PubMed ID: 24424626
[TBL] [Abstract][Full Text] [Related]
40. Social class, race/ethnicity, and incidence of breast, cervix, colon, lung, and prostate cancer among Asian, Black, Hispanic, and White residents of the San Francisco Bay Area, 1988-92 (United States).
Krieger N; Quesenberry C; Peng T; Horn-Ross P; Stewart S; Brown S; Swallen K; Guillermo T; Suh D; Alvarez-Martinez L; Ward F
Cancer Causes Control; 1999 Dec; 10(6):525-37. PubMed ID: 10616822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
